Orchid Pharma
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Orchid Pharma is navigating a pivotal transition from a traditional API manufacturer to a more integrated anti-infective platform, as highlighted by management's focus on vertical integration and expansion into regulated markets. The completion of the Dhanuka Laboratories merger is expected to enhance operational capabilities and R&D, positioning the company to capitalize on high-value opportunities, particularly in the U.S. market. Despite facing pricing pressures in the antibiotic sector, management's belief that the worst is behind them supports Vista's forecast of improving margins and revenue recovery. The company's disciplined approach to capital allocation and operational efficiency is crucial for sustaining profitability. Industry dynamics, including the shift towards Indian CDMOs and regulatory changes, further bolster the outlook, although raw material supply constraints remain a watchpoint. Over the next 12-24 months, key opportunities include successful execution of the 7-ACA project and gaining approvals for sterile generics, while headwinds may arise from geopolitical risks and competitive pricing pressures
Why We Like This Stock
- Management's focus on vertical integration and expansion into regulated markets is expected to enhance revenue growth
- The completion of the Dhanuka Laboratories merger will provide a stronger operational and R&D foundation for future growth
- Improving margins are anticipated as the company navigates pricing pressures and emphasizes cost discipline
Things To Watch Out For
- Geopolitical risks and supply chain constraints may impact operational efficiency and margin expansion
- Competitive pricing pressures in the antibiotic sector could temper revenue growth despite management's optimism
- The successful execution of the 7-ACA project and timely regulatory approvals are critical and pose execution risks
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 819 | 922 | 811 | 913 | 1,021 |
| Profit Before Tax (Cr.) | 92 | 96 | 28 | 39 | 41 |
| PBT Margin | 11.3% | 10.4% | 340.0% | 4.2% | 4.0% |
| Net Profit (Cr.) | 89 | 100 | 28 | 29 | 31 |
| Earnings Per Share | 17.5 | 19.7 | 5.5 | 5.7 | 6.1 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, macrolide, fluoroquinolone, and imidazole. The company also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is headquartered in Chennai, India. Orchid Pharma Limited operates as a subsidiary of Dhanuka Laboratories Limited.